Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.

Nature communications - 4 Jun 2026

Elliott Mitchell J, Fuentes-Antrás Jesús, Main Sasha C, Dou Aaron, Shah Elizabeth, Weipert Caroline, Yalamanchili Geethika, Bird Taylor, Roh June, Yu Celeste, Nadler Michelle B, Amir Eitan, Berman Hal K, Siu Lillian L, Bedard Philippe L, Cescon David W

Abstract excerpt

Circulating tumor DNA (ctDNA) enables minimally invasive treatment monitoring, yet the clinical validity of longitudinal ctDNA surveillance in metastatic breast cancer remains incompletely defined. Here we show that methylation-based tumor fraction (mTF), a tissue-agnostic epigenomic measure of ctDNA, closely mirrors radiographic response and clinical outcomes in 57 patients with estrogen receptor-positive,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 6

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Estrogen Receptor alpha

Share to Neoplasm Metastasis

Share to Retinoblastoma Binding Proteins

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 42243127
DOI: 10.1038/s41467-026-73126-9
PMCID: PMC13396465

Genes

CDK4
ESR1
RB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy.PMID 42243127Read ↗

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.Semantic proximity Read ↗

Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer StudySemantic proximity Read ↗

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerSemantic proximity Read ↗

ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.Semantic proximity Read ↗

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast CancerSemantic proximity Read ↗

Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQSemantic proximity Read ↗

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancerSemantic proximity Read ↗

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read ↗

Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.Semantic proximity Read ↗

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.